Bioventus agreed to a U.S. contract with UnitedHealthcare Employer & Individual commercial plans. In October, UnitedHealthcare commercial plan members will have access to DUROLANE and GELSYN-3 to treat knee osteoarthritis pain. DUROLANE is a single-injection and GELSYN-3, a three-injection hyaluronic acid-based joint-fluid treatment for patients.
“We are pleased DUROLANE and GELSYN-3 are among the preferred options available to UnitedHealthcare members and physicians,” said John Nosenzo, Chief Commercial Officer, Bioventus. “Both now have access to two safe HA products that are proven to provide relief from knee OA pain.”
Bioventus agreed to a U.S. contract with UnitedHealthcare Employer & Individual commercial plans. In October, UnitedHealthcare commercial plan members will have access to DUROLANE and GELSYN-3 to treat knee osteoarthritis pain. DUROLANE is a single-injection and GELSYN-3, a three-injection hyaluronic acid-based joint-fluid treatment for...
Bioventus agreed to a U.S. contract with UnitedHealthcare Employer & Individual commercial plans. In October, UnitedHealthcare commercial plan members will have access to DUROLANE and GELSYN-3 to treat knee osteoarthritis pain. DUROLANE is a single-injection and GELSYN-3, a three-injection hyaluronic acid-based joint-fluid treatment for patients.
“We are pleased DUROLANE and GELSYN-3 are among the preferred options available to UnitedHealthcare members and physicians,” said John Nosenzo, Chief Commercial Officer, Bioventus. “Both now have access to two safe HA products that are proven to provide relief from knee OA pain.”
Copy to clipboard 
